On March 6, 2023, the grand opening ceremony of Creative Biosciences (Hong Kong) Co., Limited was observed. Dr. Hongzhi Zou, the founder of Creative Biosciences, led the whole international business development team to Hong Kong. In the presence of industry partners, CreativeBio Hong Kong branch was officially established.

Dr. Zou stated, "Backed by our homeland, rooted in the Greater Bay Area, established in Hong Kong, and oriented towards the world, this marks a great starting point for our global expansion. In our journey towards the international market, we have made full preparations in terms of funding, business, and talent. We hope that the establishment of the Hong Kong subsidiary will further propel CreativeBio towards internationalization, enabling us to better serve customers in Hong Kong, Southeast Asia, and other regions worldwide."

Serving human health is the noble mission of us at CreativeBio. Based on the development requirements of the new era, CreativeBio is expanding overseas and embarking on a new journey. Colosafe^®, fecal DNA test for early detection of colorectal cancer, was approved in November 2018 by NMPA, making it the first of its kind in China. It has accumulated real-world application testing data from over 560,000 cases and fulfilled a full-chain system for the research and development, production, supply, and service of raw materials related to DNA testing for cancer. Additionally, it has created innovative model that effectively improve early cancer diagnosis rate and survival rate, providing replicable and scalable clinical and screening experience for major disease prevention and control. Evidently this has benefited the public and helps local governments save financial expenditures.

After the opening ceremony, Dr. Zou, Mr. Liao Jihong and Chi Junlin who are the international business leaders, along with Wong Ting Yan, Chief Operating Officer of KingMed Diagnostics (Hong Kong), Li Miaozhi, laboratory head of KingMed Diagnostics (Hong Kong), and Mr. Liu Jiancheng, founder of Chengda Consulting Company, engaged in in-depth discussions and exchanges on various topics, including the interconnection of the Guangdong-Hong Kong-Macao Greater Bay Area, the integration and development of the Hong Kong market, cancer genetic testing technology, and overseas market expansion. These discussions further strengthened CreativeBio’s confidence in its international expansion.

Hong Kong, as a crucial hub of international ports, serves as an important platform for CreativeBio to enter global market. The foramation of Hong Kong branch brings the accumulated practical testing experience and new cancer screening models from mainland China to Hong Kong. This move will considerably reinforce exchanges and cooperation with international markets, accelerating the achievement of our business internationalization strategy and building a more diversified service system in the field of molecular diagnostics. With professionalism and strength, we are committed to the realizing of human health, expanding to international market, and safeguarding human health!